• Explore /
  • Poster
  • / Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.

Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.

Abstract Poster

Authors

null

Matthew R. Smith

Harvard Medical School and Massachusetts General Hospital, Boston, MA

Matthew R. Smith , Shannon Matheny , Fred Saad , Dana E. Rathkopf , Peter F.A. Mulders , Johann Sebastian De Bono , Eric Jay Small , Neal D. Shore , Karim Fizazi , Thian San Kheoh , Jinhui Li , Mary Beth Todd , Thomas W. Griffin , Margaret K. Yu , Charles J. Ryan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT00887198

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 21)

DOI

10.1200/jco.2014.32.4_suppl.21

Abstract #

21

Poster Bd #

B5

Abstract Disclosures

Similar Posters

First Author: Thomas W. Flaig

First Author: Emily Nash Smyth

First Author: Stephen J. Freedland

First Author: Alicia K. Morgans